Intravacc and DZNE awarded EU funding to develop vaccine against genetic ALS variant
Intravacc and DZNE awarded EU funding to develop vaccine against genetic ALS variant Bilthoven, the Netherlands / Munich, Germany, 6 July 2022 – Intravacc, a world leading contract development and manufacturing organization (CDMO) of preventive and therapeutic vaccines and the…
- Total amount of €2.5 million for amyotrophic lateral sclerosis (ALS) vaccine development
- ALS vaccine is targeting the most common genetic ALS variant
- 5-10% of all ALS cases are caused by a mutation in the C9orf72 gene